Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Clinuvel Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLVLF.

Revenue growth5.2% · median 17.8%

Gross margin82.9% · median 69.2%

Operating margin43.4% · median -14.2%

Net margin36.0% · median 23.5%

Advertisement
300 × 250

See a number that looks wrong?